← Back to Clinical Trials
Recruiting NCT07705269

NCT07705269 The FILTRATE Trial: High-Rate Ultrafiltration for Intravascular Congestion

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07705269
Status Recruiting
Phase —
Sponsor Universidad Autonoma de Nuevo Leon
Condition End Stage Chronic Renal Failure
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2026-06-04
Primary Completion 2027-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
High-rate ultrafiltrationStandard fluid removal

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2026-06-04 with a primary completion date of 2027-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to evaluate whether a personalized, high-rate fluid removal strategy guided by ultrasound is as safe and effective as the standard fluid removal rate for patients with advanced kidney disease who are hospitalized due to severe fluid overload (congestion). When patients with End-Stage Renal Disease (ESRD) on chronic hemodialysis are admitted to the hospital with excess fluid, doctors often need to remove this fluid quickly to relieve symptoms like severe shortness of breath. However, traditional guidelines recommend conservative fluid removal rates-called ultrafiltration (UF) rates-between 10 and 13 mL/kg/h to prevent sudden drops in blood pressure (intradialytic hypotension). Despite these guidelines, doctors in real-world hospital settings frequently use higher rates to provide urgent relief, though this practice lacks strong scientific backing. This study utilizes advanced bedside ultrasound protocols (such as lung ultrasound and VExUS) to objectively measure the amount of fluid congestion inside the patient's blood vessels. The researchers hypothesize that patients with high ultrasound markers of congestion can safely tolerate higher fluid removal rates because their blood vessels are overfilled, meaning fluid can be pulled out faster without causing blood pressure drops. Participants will be randomly assigned to one of two groups during their first in-hospital hemodyalisis session: * Standard Group: Receives a standard fluid removal rate of 10 mL/kg/h. * High-Rate Group: Receives a higher fluid removal rate of over 13 mL/kg/h (with a safety ceiling up to 15 mL/kg/h). The study will compare the two groups over the first 24 hours to monitor blood pressure stability (safety) and check for improvements in ultrasound congestion scores, shortness of breath, and the need for supplemental oxygen (effectiveness).

Eligibility Criteria

Inclusion Criteria: * Adults over 18 years old with End-Stage Renal Disease on hemodialysis for at least 3 months. * Admitted to the hospital requiring mechanical fluid removal for acute fluid overload (first in-hospital session). * Clear ultrasound evidence of severe intravascular congestion (such as diffuse B-lines in the lungs or altered VExUS vascular flow patterns). * Hemodynamically stable with a baseline blood pressure of at least 120/80 mmHg. Exclusion Criteria: * Baseline low blood pressure (\<100/60 mmHg) or active shock (cardiogenic, septic, or distributive). * Acute coronary syndrome (heart attack), severe heart valve disease, or severe fluid around the heart. * Known chronic lung disease. * Pregnancy.

Contact & Investigator

Central Contact

Edgar Adrián Montemayor, Nephrology Fellow

✉ edgar.montemayorga@uanl.edu.mx

📞 +52 8180911271

Frequently Asked Questions

Who can join the NCT07705269 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying End Stage Chronic Renal Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07705269 currently recruiting?

Yes, NCT07705269 is actively recruiting participants. Contact the research team at edgar.montemayorga@uanl.edu.mx for enrollment information.

Where is the NCT07705269 trial being conducted?

This trial is being conducted at Monterrey, Mexico.

Who is sponsoring the NCT07705269 clinical trial?

NCT07705269 is sponsored by Universidad Autonoma de Nuevo Leon. The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology